Showing results (111-120 of 118) with videos related to
Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
The Journal of Pharmacology and Experimental Therapeutics|April 25, 2008
Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic ratsJames G Conway, Heather Pink, Mandy L Bergquist, et al.Journal of Medicinal Chemistry|November 16, 2001
Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)M H Rabinowitz, R C Andrews, J D Becherer, et al.Proceedings of the National Academy of Sciences of the United States of America|October 27, 2005
Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580James G Conway, Brad McDonald, Janet Parham, et al.The Journal of Pharmacology and Experimental Therapeutics|August 16, 2001
Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinasesJ G Conway, R C Andrews, B Beaudet, et al.Journal of Medicinal Chemistry|January 23, 1998
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonistsM L Curtin, S K Davidsen, H R Heyman, et al.MMWR Supplements|December 22, 2006
Engineering and public health at CDCG Scott Earnest, Laurence D Reed, D Conover, et al.Bioorganic & Medicinal Chemistry Letters|August 22, 2001
N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitutionD L Musso, M W Andersen, R C Andrews, et al.American Heart Journal|February 12, 2022
Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trialMandeep S Sidhu, Karen P Alexander, Zhen Huang, et al.Pageof 12